Aventis Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Schilitgheim France (1999)
Status: Acquired by Sanofi-Synthelabo (2004) → now Sanofi-Aventis (2004)

Organization Overview

First Clinical Trial
1999
NCT00002662
First Marketed Drug
2000
insulin glargine (toujeo)
First NDA Approval
2000
insulin glargine (toujeo)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aventis Pharmaceuticals

Active Ingredients

Marketed Drugs (4)

dalfopristin (Synercid) (NDA)

insulin glargine (toujeo) (2000 NDA)

insulin glulisine (Apidra) (2004 NDA)

telithromycin (ketek) (2004 NDA)

Drugs in Phase 4 Trials (5)

Key: Aventis (3) Acquired (2)

celiprolol (1 trial)

enoxaparin (lovenox) (3 trials)

insulin glargine (toujeo) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

sitagliptin (januvia) (2 trials)

Drugs in Phase 3 Trials (19)

Key: Aventis (16) Acquired (3)

atorvastatin (lipitor) (2 trials)

calcitriol (rocaltrol) (2 trials)

carboplatin (paraplatin) (13 trials)

cisplatin (platinol) (8 trials)

cyclophosphamide (cytoxan) (3 trials)

dalfopristin (Synercid) (1 trial)

docetaxel (taxotere) (52 trials)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (4 trials)

irinotecan (Camptosar) (6 trials)

leucovorin (3 trials)

levocarnitine (carnitor) (1 trial)

naltrexone (revia) (1 trial)

paclitaxel (taxol) (1 trial)

quinupristin (1 trial)

ramipril (altace) (2 trials)

riluzole (rilutek) (1 trial)

telmisartan (micardis) (1 trial)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 2 Trials (30)

Key: Aventis (22) Acquired (8)

alvac-hiv vaccine (1 trial)

amifostine (ethyol) (1 trial)

azithromycin (zithromax) (1 trial)

bortezomib (velcade) (1 trial)

capecitabine (xeloda) (4 trials)

clarithromycin (biaxin) (1 trial)

doxorubicin (Doxil) (4 trials)

epirubicin (ellence) (3 trials)

erlotinib (tarceva) (3 trials)

erythromycin (ilosone) (1 trial)

estramustine (emcyt) (3 trials)

ethambutol (myambutol) (1 trial)

gefitinib (iressa) (2 trials)

gemcitabine (gemzar) (7 trials)

hby 097 (1 trial)

imatinib (gleevec) (1 trial)

lipo-5 (1 trial)

lipo-6t (1 trial)

mdl 28574 (3 trials)

oxaliplatin (eloxatin) (1 trial)

pi-88 (1 trial)

prednisone (meticorten) (1 trial)

recombinant adenoviral human p53 gene (1 trial)

rifapentine (priftin) (1 trial)

sargramostim (leukine) (2 trials)

topotecan (hycamtin) (1 trial)

trastuzumab (herceptin) (5 trials)

vinorelbine (navelbine) (3 trials)

zidovudine (retrovir) (2 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 1 Trials (9)

Key: Aventis (5) Acquired (4)

aldesleukin (Proleukin) (1 trial)

dac-30 (1 trial)

garlic (2 trials)

hiv-1 gp 160 (1 trial)

immune globulin (human) (Gamastan) (1 trial)

pentoxifylline (trental) (1 trial)

sch66336 (1 trial)

spiramycin (2 trials)

temozolomide (temodar) (1 trial)

Drugs in Other Trials (16)

Key: Aventis (2) Acquired (14)

alirocumab (praluent) (1 trial)

bifidobacterium lactis (1 trial)

c6 ketone di-ester (1 trial)

gingerol (1 trial)

isoniazid (nydrazid) (1 trial)

maltodextrin (1 trial)

pentamidine (pentam) (5 trials)

pyrazinamide (Aldinamide) (1 trial)

pyridoxine (1 trial)

rifampin (1 trial)

risedronate (actonel) (1 trial)

sc-fos (1 trial)

thiethylperazine (torecan) (1 trial)

thiocarb (2 trials)

totum-63 (1 trial)

turmeric (1 trial)

Indications

Approved Indications


 

Bronchitis, Chronic

Diabetes, Gestational

Diabetes Mellitus

Diabetes Mellitus, Type 1

Diabetes Mellitus, Type 2

Pneumonia

Pneumonia, Bacterial

Sinusitis

Skin Diseases, Infectious

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Atrophy (Phase 3)

Bacterial Infections (Phase 3)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiovascular Diseases (Phase 3)

Colorectal Neoplasms (Phase 1)

Communicable Diseases (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Digestive System Neoplasms (Phase 2)

Disease Progression (Phase 3)

Ehlers-Danlos Syndrome (Phase 4)

Esophageal Neoplasms (Phase 3)

Gastrointestinal Neoplasms (Phase 2)

Glucose Intolerance (Phase 3)

Glucose Metabolism Disorders (Phase 3)

Gram-Positive Bacterial Infections (Phase 3)

Head and Neck Neoplasms (Phase 2)

HIV Infections (Phase 2)

Hypertension (Phase 3)

Infections (Phase 2)

Inflammatory Breast Neoplasms (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Lung Neoplasms (Phase 3)

Melanoma (Phase 1)

Metabolic Diseases (Phase 3)

Multiple System Atrophy (Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasms, Squamous Cell (Phase 2)

Otitis (Phase 3)

Otitis Media (Phase 3)

Otitis Media with Effusion (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Pleural Effusion (Phase 2)

Prostatic Neoplasms (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Rhinitis (Phase 3)

Sarcoma (Phase 1)

Shy-Drager Syndrome (Phase 3)

Small Cell Lung Carcinoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Supranuclear Palsy, Progressive (Phase 3)

Syndrome (Phase 4)

Thrombosis (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Venous Thrombosis (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 99
  • # of Trial APIs: 79